|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-5-19
|
|
pubmed:abstractText |
Erythropoiesis stimulating agent (ESA) resource utilisation in cancer chemotherapy patients is of importance to managed-care organisations. To understand current real-world utilisation of ESAs, this study examined epoetin alfa (EPO) and darbepoetin alfa (DARB) treatment patterns (dosing and treatment duration), dose ratio and ESA treatment costs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1369-6998
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19450059-Anemia,
pubmed-meshheading:19450059-Antineoplastic Agents,
pubmed-meshheading:19450059-Drug Costs,
pubmed-meshheading:19450059-Drug Utilization,
pubmed-meshheading:19450059-Erythropoietin,
pubmed-meshheading:19450059-Female,
pubmed-meshheading:19450059-Hematinics,
pubmed-meshheading:19450059-Humans,
pubmed-meshheading:19450059-Insurance Claim Review,
pubmed-meshheading:19450059-Male,
pubmed-meshheading:19450059-Managed Care Programs,
pubmed-meshheading:19450059-Middle Aged,
pubmed-meshheading:19450059-Neoplasms,
pubmed-meshheading:19450059-Recombinant Proteins,
pubmed-meshheading:19450059-Retrospective Studies
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
|
|
pubmed:affiliation |
Groupe d'analyse, Ltée, Montréal, Québec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
